Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2019

Primary Completion Date

May 26, 2022

Study Completion Date

September 27, 2022

Conditions

Metastatic Hepatocellular CarcinomaHCCCombinations of Drugs; Dependence

Interventions

DRUG

GT90001 and Nivolumab

Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Trial Locations (3)

National Cheng Kung University Hospital, Tainan City

MacKay Memorial Hospital, Taipei

National TaiWan University Hospital, Taipei

All Listed Sponsors

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT03893695 - Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | Biotech Hunter | Biotech Hunter